全文获取类型
收费全文 | 16761篇 |
免费 | 1368篇 |
国内免费 | 74篇 |
学科分类
医药卫生 | 18203篇 |
出版年
2023年 | 148篇 |
2022年 | 112篇 |
2021年 | 431篇 |
2020年 | 325篇 |
2019年 | 464篇 |
2018年 | 549篇 |
2017年 | 365篇 |
2016年 | 430篇 |
2015年 | 503篇 |
2014年 | 691篇 |
2013年 | 835篇 |
2012年 | 1217篇 |
2011年 | 1281篇 |
2010年 | 745篇 |
2009年 | 671篇 |
2008年 | 1052篇 |
2007年 | 1148篇 |
2006年 | 1061篇 |
2005年 | 1034篇 |
2004年 | 934篇 |
2003年 | 858篇 |
2002年 | 661篇 |
2001年 | 364篇 |
2000年 | 296篇 |
1999年 | 262篇 |
1998年 | 147篇 |
1997年 | 126篇 |
1996年 | 106篇 |
1995年 | 86篇 |
1994年 | 91篇 |
1993年 | 89篇 |
1992年 | 129篇 |
1991年 | 114篇 |
1990年 | 109篇 |
1989年 | 101篇 |
1988年 | 80篇 |
1987年 | 74篇 |
1986年 | 68篇 |
1985年 | 63篇 |
1984年 | 54篇 |
1983年 | 42篇 |
1982年 | 37篇 |
1981年 | 36篇 |
1980年 | 29篇 |
1979年 | 26篇 |
1978年 | 24篇 |
1977年 | 29篇 |
1976年 | 16篇 |
1975年 | 13篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
3.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
4.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
5.
6.
7.
8.
9.
10.
Prevalence of Potentially Inappropriate Prescribing Among Hong Kong Older Adults: A Comparison of the Beers 2003, Beers 2012, and Screening Tool of Older Person's Prescriptions and Screening Tool to Alert doctors to Right Treatment Criteria 下载免费PDF全文